Cue Biopharma (CUE)
(Delayed Data from NSDQ)
$1.65 USD
-0.06 (-3.51%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $1.65 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.65 USD
-0.06 (-3.51%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $1.65 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Zacks News
Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari
by Zacks Equity Research
Alnylam (ALNY) announces preliminary results for the fourth quarter and 2019 and provides other updates.
Ultragenyx's Gene Therapy Positive in Genetic Disorder Study
by Zacks Equity Research
Shares of Ultragenyx (RARE) rise 23.4% after releasing positive top-line data from the phase I/II study of its gene therapy candidate DTX301 for the treatment of OTC deficiency.
The Zacks Analyst Blog Highlights: EverQuote, Cassava Sciences, Fulgent Genetics, Teekay Tankers and Cue Biopharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: EverQuote, Cassava Sciences, Fulgent Genetics, Teekay Tankers and Cue Biopharma
5 Stocks to Soar in 2020 After Solid Gains in 2019
by Zacks Equity Research
U.S. stocks rallied to attained fresh all-time highs in 2019, as the momentum continued in 2020. Here are five stocks that are poised to grow.
Are You Looking for a Top Momentum Pick? Why Cue Biopharma, Inc. (CUE) is a Great Choice
by Zacks Equity Research
Does Cue Biopharma, Inc. (CUE) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Biotech Stocks That Have More Than Doubled This Year
by Ekta Bagri
The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
5 Biotech Stocks Up More Than 100% This Year So Far
by Indrajit Bandyopadhyay
The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.
Here's Why Cue Biopharma, Inc. (CUE) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Cue Biopharma, Inc. (CUE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cue Biopharma, Inc. (CUE) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cue Biopharma, Inc. (CUE).
What Makes Cue Biopharma, Inc. (CUE) a New Strong Buy Stock
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).